Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 2/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.37 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | MMP9 | P14780 | 2/20 | 0.33 |
| ▸ | MMP12 | P39900 | 2/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | FABP7 | O15540 | 1/20 | 0.32 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2956734 | 0.86 | EPHX1 (0.42) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL5398616 | 0.84 | EPHX1 (0.43) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL6007716 | 0.83 | EPHX1 (0.46) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL8579936 | 0.82 | EPHX1 (0.42) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL1021168 | 0.82 | EPHX1 (0.42) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL1559459 | 0.82 | EPHX1 (0.42) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL8631017 | 0.82 | NAAA (0.50) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL11589171 | 0.82 | NAAA (0.50) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL1023656 | 0.82 | EPHX1 (0.42) | EPHX1HTTCYP2C19NAAACYP19A1 | |
| SCHEMBL11590190 | 0.82 | NAAA (0.50) | EPHX1HTTCYP2C19NAAACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048273-A1 | PREMATURE OVULATION PREVENTIVE AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20080207524-A1 | MEDICINAL PREPARATIONS FOR TREATING SEX HORMONE-DEPENDENT DISEASES | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2008-08-28 | — | — | US | disclosed |
| EP-1917978-A1 | PREMATURE OVULATION PREVENTIVE AGENT | Takeda Pharmaceutical Company Limited (JP) | 2008-05-07 | — | — | EP | disclosed |
| US-20050250793-A1 | Preventives/remedies for hot flash | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-10 | — | — | US | disclosed |
| EP-1495768-A1 | PREVENTIVES/REMEDIES FOR HOTFLASH | Takeda Pharmaceutical Company Limited (JP) | 2005-01-12 | — | — | EP | disclosed |
| US-20040116522-A1 | Medicinal solutions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-06-17 | — | — | US | disclosed |
| EP-1163244-B1 | THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2004-03-10 | — | — | EP | disclosed |
| EP-1393747-A1 | PREVENTIVES/REMEDIES FOR ALZHEIMER'S DISEASE | Takeda Chemical Industries, Ltd. (JP) | 2004-03-03 | — | — | EP | disclosed |
| US-20040034039-A1 | Solid preparations | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-19 | — | — | US | disclosed |
| US-20040023987-A1 | Sustained release compositions | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1163244-A1 | THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-12-19 | — | — | EP | disclosed |
| US-6329388-B2 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E.G., SEX HORMONE-DEPENDENT CANCERS (E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| US-6297379-B1 | GONADOTROPIN RELEASING HORMONE (GNRH, SOMETIMES CALLED LH-RH (LUTEINIZING HORMONE RELEASING HORMONE)) ANTAGONIZING ACTIVITY, TREATING SEX HORMONE-DEPENDENT DISEASES. | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-6297255-B1 | GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-10-02 | — | — | US | disclosed |
| US-6262267-B1 | HAS GONADOTROPIN-RELEASING HORMONE ANTAGONIZING ACTIVITY; USEFUL FOR PREVENTING OR TREATING SEX HORMONE-DEPENDENT DISEASES, E,G., SEX HORMONE-DEPENDENT CANCERS E.G., PROSTATIC CANCER, UTERINE CANCER, BREAST CANCER, PITUITARY TUMOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-17 | — | — | US | disclosed |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | FURUYA SHUICHI (JP) | 2001-05-10 | — | — | US | disclosed |
| EP-1090010-A1 | THIENOPYRIDINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2001-04-11 | — | — | EP | disclosed |
| CN-1284075-A | Novel compounds having CGMP-PDE inhibitory effect | MOCHIDA PHARM CO LTD (JP) | 2001-02-14 | — | — | CN | disclosed |
| WO-2000056739-A1 | THIENOPYRIMIDINE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000000493-A1 | THIENOPYRIDINE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207524-A1 | MEDICINAL PREPARATIONS FOR TREATING SEX HORMONE-DEPENDENT DISEASES | SHBG, GNRHR, NR5A1 | EPHX1 3103/4885HTT 679/4885CYP2C19 2119/4885 |
| US-20040023987-A1 | Sustained release compositions | NGLY1, GHSR, GHRHR | EPHX1 4077/4885HTT 1836/4885CYP2C19 1577/4885 |
| US-20010001104-A1 | Thienopyridine compounds, their production and use | PRLHR, PGR, GNRHR | EPHX1 1799/4885HTT 906/4885CYP2C19 1084/4885 |
| US-20050250793-A1 | Preventives/remedies for hot flash | GNRHR, SHBG, FSHR | EPHX1 2074/4885HTT 1260/4885CYP2C19 2674/4885 |
| US-20040034039-A1 | Solid preparations | GYS1, GYS2, SI | EPHX1 2338/4885HTT 3970/4885CYP2C19 840/4885 |
| US-20090048273-A1 | PREMATURE OVULATION PREVENTIVE AGENT | GNRHR, FSHR, LHCGR | EPHX1 3481/4885HTT 1229/4885CYP2C19 2131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.